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Some of the results of these studies have been previously reported in the form of a preprint 
(bioRxiv, [18 December 2020] https://doi.org/10.1101/2020.12.18.423415). 
This article is open access and distributed under the terms of the Creative Commons 
Attribution Non-Commercial No Derivatives License 4.0 
(http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints 
please contact Diane Gern (dgern@thoracic.org).
Page 3 of 55
 AJRCMB Articles in Press. Published March 30, 2021 as 10.1165/rcmb.2021-0005OC 
 Copyright © 2021 by the American Thoracic Society 
Abstract
COVID -19 is an acute infectious disease caused by the Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2). Human surfactant protein D (SP-D) is known to interact with 
spike protein of SARS-CoV, but its immune-surveillance against SARS-CoV-2 is not known. 
The study aimed to examine the potential of a recombinant fragment of human SP-D (rfhSP-
D) as an inhibitor of replication and infection of SARS-CoV-2. The interaction of rfhSP-D 
with spike protein of SARS-CoV-2 and hACE-2 receptor was predicted via docking analysis. 
The inhibition of interaction between spike protein and ACE-2 by rfhSP-D was confirmed 
using direct and indirect ELISA. The effect of rfhSP-D on replication and infectivity of 
SARS-CoV-2 from clinical samples was studied by measuring the expression of RdRp gene 
of the virus using qPCR. In-silico interaction studies indicated that three amino acid residues 
in the RBD of spike of SARS-CoV-2 were commonly involved in interacting with rfhSP-D 
and ACE-2. Studies using clinical samples of SARS-CoV-2 positive cases (asymptomatic, 
n=7 and symptomatic, n=8 and negative controls n=15) demonstrated that treatment with 
1.67 µM rfhSP-D inhibited viral replication by ~5.5 fold and was more efficient than 
Remdesivir (100 µM). Approximately, a 2-fold reduction in viral infectivity was also 
observed after treatment with 1.67 µM rfhSP-D. These results conclusively demonstrate that 
the calcium independent rfhSP-D mediated inhibition of binding between the receptor 
binding domain of the S1 subunit of the SARS-CoV-2 spike protein and human ACE-2, its 
host cell receptor, and a significant reduction in SARS-CoV-2 infection and replication in-
vitro.   
Word Count:246
Keywords: SARS-CoV-2, COVID-19, Surfactant protein D, innate immunity, Spike protein, 
infection, Entry inhibitor
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Introduction
The COVID-19 pandemic, caused by the ‘Severe acute respiratory syndrome Coronavirus-2’ 
(SARS-CoV-2) (1, 2),  has affected ~ 58 million people across the globe and has claimed 
more than a million lives within its first year (3). The SARS-CoV-2 spike protein (S protein) 
is cleaved into S1 subunit, which is involved in host receptor binding, and S2 subunit, which 
is involved in membrane fusion, by the host’s transmembrane Serine Protease 2 (TMPRSS2) 
(4). This priming of the S protein by host proteases enables it to bind with the angiotensin-
converting enzyme 2 (ACE2) receptor on the nasopharyngeal epithelial cells, leading to its 
entry into the host cell (4). While vaccines against the virus are being continually developed 
and trialled, therapeutic strategies to treat severe COVID-19 cases are limited and comprise 
of Remdesivir and Dexamethasone (5).
The innate immune system plays a crucial role against SARS-CoV-2 infection; majority of 
infected individuals purge the virus within a few days with minimal involvement of adaptive 
immune response (6).  Collectins are a group of humoral pattern recognition receptors, of 
which human lung surfactant protein D (SP-D), is known to act as a potent viral entry 
inhibitor, including HIV-1 and influenza A virus (7, 8). The primary structure of SP-D is 
characterised by an N-terminus that is involved in multimerization; a triple-helical 
collagenous region made up of Gly-X-Y repeats, an α-helical coiled-coil neck region, and a 
C-terminal C-type lectin or carbohydrate recognition domain (CRD) (9). The protective 
effects of SP-D against a range of bacterial, viral, and fungal pathogens leading to their 
agglutination, growth inhibition, enhanced phagocytosis, neutralisation, and modulation of 
immune responses are well documented (9, 10).
During the SARS-CoV epidemic in 2002, elevated levels of SP-D were reported in the serum 
of the patients infected with highly pathogenic β-CoV, SARS CoV (11). Purified SP-D has 
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been shown to bind to the receptor-binding domain (RBD) of the glycosylated Spike protein 
of SARS-CoV, which shares 74% homology with the RBD of SARS-CoV-2 (12). In 
addition, SP-D also binds α-CoV, HCoV-229E, and inhibits infection in human bronchial 
epithelial cells (13). These mounting pieces of evidence encouraged exploration of the 
therapeutic potential of SP-D in COVID-19 patients. 
In this study, we used a well-characterised recombinant fragment of human SP-D (rfhSP-D) 
comprising homotrimeric neck and CRD regions to study its protective effect against SARS-
CoV-2 infection. As the recombinant form has the advantage of a smaller size to reach the 
distal lung locations and higher resistance to proteases and collagenases over the full-length 
SP-D, we evaluated the interaction of rfhSP-D with RBD and Spike of SARS-CoV-2 and its 
inhibitory potential against infection and replication of SARS-CoV-2 in clinical samples. 
Materials and Methods
An additional detailed section for performing these experiments is provided in an online data 
supplement.
Clinical Samples  
The clinical samples (throat and nasal swabs) (n=15) (Table 1) were from symptomatic 
contacts of lab-confirmed cases (Cat 2) (n=2), hospitalised severe acute respiratory infections 
(SARI) patients (Cat 4) (n=3), asymptomatic direct and high-risk contacts of lab-confirmed 
cases (Cat 5a) (n=7) and hospitalised symptomatic influenza-like illness (ILI) patients (Cat 6) 
(n=3) that had tested positive by RT-PCR test for SARS-CoV-2. Samples (n=15) that tested 
negative by RT-PCR test for SARS-CoV-2 were used as controls. The inclusion criteria for 
the cases were age (between 18-45 years) and a Ct value between 10 and 15 (18-45 years and 
an undetectable viral load for controls). The two groups showed no significant difference in 
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their age and sex distribution. The 50% Tissue culture Infective Dose (TCID50) of the clinical 
samples was estimated using a template that utilized the  Spearman & Kärber method for 
calculation (14). The TCID50 value estimated was further confirmed via MTT assay. Briefly, 
5 x 104 Vero cells in Vero growth media [MEM Glutamax+10% FBS, 1% Penicillin-
Streptomycin and 1% sodium pyruvate (Gibco)] were grown in a 96-well plate overnight. 
The clinical samples from the cases and controls at various dilutions were added to the cells, 
incubated for 1h, wells were washed with PBS twice, and fresh Vero growth medium was 
added to the cells and incubated (96h, 37oC, 5% CO2). MTT assay was performed to assess 
cell viability. 
In silico analysis of rfhSP-D interaction with SARS-CoV-2 spike(S) protein and hACE-2 
Structural information with respect to the molecular interactions between S-protein and 
hACE2 are available (15, 16). The rfhSP-D trimer (pdb id: 1PW9) was blind-docked with (a) 
RBD of S protein in open conformation (pdb id: 6VYB) and (b) dimeric hACE2 (pdb id: 
6VW1). Top 100 docked poses selected were further refined using FireDock web server (17, 
18) for calculating global free energy. The top five refined structures were filtered based on 
interactions between RBM of S protein, C-Type Lectin Domain (CTLD:  aa 240-355) of 
rfhSP-D and N-terminal of hACE2. 
The effect of binding of trimeric rfhSP-D to S-protein and dimeric ACE2 on ACE2 - S 
protein interaction was evaluated by further docking the docked complex of (a) S protein and 
rfhSP-D with hACE2 and (b) hACE2 and rfhSP-D with S protein. Patchdock web server (19, 
20) was used for all docking experiments.
In silico interaction of single residue rfhSP-D mutants with Spike protein and hACE-2
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The importance of rfhSP-D residues predicted to be interacting with ACE-2 and S protein 
was further validated using single residue mutations in the docked complex using mCSM-
PPI2 web server (21). Each of the rfhSP-D residues involved in interaction with virus-binding 
hotspot of ACE-2 and RBD of S protein were mutated to the standard amino acids and its 
effect on binding energy of the complex was assessed.
ELISA
The rfhSP-D used was expressed and purified from E. coli as described previously (22, 23). 
rfhSP-D binding to S protein or RBD was analysed using the SARS-CoV-2 Inhibitor 
Screening Kit (Acro Biosystems; EP-105). 
Microtitre wells were coated with 0.3 µg/ml (0.54 nM) S protein and incubated with rfhSP-D 
(20, 10 and 5 µg/ml or 0.334, 0.167, 0.083 µM) or FL SP-D (20 µg/ml or 0.038 µM) for 1h at 
370C in PBS supplemented with 5mM CaCl2. After blocking and washing, the wells were 
incubated with polyclonal or monoclonal antibodies against SP-D (1 mg/ml) and probed with 
their respective secondary antibodies conjugated with HRP.  The binding was detected using 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate and absorbance was recorded at 450 nm. 
Similarly, to ascertain calcium-dependence of interaction, binding assay was carried out with 
10mM EDTA.
rfhSP-D/FL SP-D and ACE-2 interaction was evaluated by coating rfhSP-D (0.1 µg/ml or 
1.67 nM) /FL SP-D (0.1 µg/ml or 0.19 nM) and probed with biotinylated hACE-2 (0.12, 0.06 
and 0.00 µg/ml or 0.52, 0.26, 0.0 nM), followed by addition of streptavidin tagged with HRP.
To assess if rfhSP-D inhibited the interaction of S protein/RBD with biotinylated hACE-2, 
rfhSP-D (5, 1 and 0 µg/ml or 83.5 nM, 16.7 nM, 0.0 nM) was pre-incubated with the coated S 
protein/RBD, followed by addition of biotinylated ACE-2. The S protein-hACE-2 binding 
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was probed with the HRP tagged Streptavidin antibody. rfhSP-D (5 µg/ml or 83.5 nM) in 
10mM EDTA was also used. 
Vero Cell Replication Assay 
Vero cells (ATCC® CCL–81™) (5x104) were cultured in serum-free MEM. SARS-CoV-2 
positive clinical samples (100 TCID50/well; MOI 0.01) were preincubated with rfhSP-D [0 
µg/ml (0 µM), 50 µg/ml (0.835 µM) or 100 µg/ml (1.67 µM)] in MEM containing 5mM 
CaCl2 for 1h at RT and 1h at 4oC (7). SARS-CoV-2 negative clinical samples (volume 
equivalent to 100 TCID50 of the age and sex matched SARS-CoV-2 positive sample/well, 
MOI 0.01) were used as control. This pre-treated or untreated virus was added to the cells and 
was incubated for 1h at 37ºC, 5% CO2. Following PBS washes, infection medium 
(MEM+0.3% BSA) was added and incubated for 24h to assess replication. Total RNA was 
extracted from cell pellet using the Perkin Elmer automated extractor. Real-time RT-PCR for 
SARS-CoV-2 was carried out using Pathodetect kits (MyLabs). For the replication analysis, 
Ct value for SARS-CoV-2 RNA dependent RNA polymerase (RdRp) gene was used. Cells 
incubated with rfhSP-D, without virus was used as the protein control. 
Vero cell Infection assay
SARS-CoV-2 positive clinical samples (500 TCID50/well, MOI 0.05) [and SARS-CoV-2 
negative clinical samples (equivalent volume)] were treated with rfhSP-D (7). After adding 
the infection medium, Vero cells (5x105) were incubated for 2h, harvested, and Real-time 
RT-PCR was performed, as described above. 
Results
rfhSP-D interacts with the Spike protein of SARS-CoV-2 and human ACE-2 in silico
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S protein is known to interact via the receptor binding motif (RBM: aa 455-508) in the 
receptor binding domain (RBD: aa 319-527) with virus binding hotspot residues comprising 
of Lys31, Glu35 and Lys353 of dimeric hACE2 (15, 16). The structure of hACE2 receptor, 
co-crystallized with Spike S protein of SARS-CoV-2, is available in RCSB (pdb id: 6VW1). 
The receptor (ACE2) and ligand (Spike S) were separated and docked to validate the docking 
protocol. The redocked complex of ACE2 and S protein had root mean square deviation 
(RMSD) of 7.9 Å. The close agreement between the docked and crystal structures validated 
the docking protocol used in the study. 
In case of docked solutions for S protein and rfhSP-D (Supplementary Figure S1), the third 
ranked docked pose with binding energy of -20.63 kcal/mol exhibited rfhSP-D interactions 
with RBM residues Tyr449, Gln493 Gln498, implying that rfhSP-D could bind to Spike 
protein in a manner that can inhibit ACE2-S protein interaction (Table 2; Figure 1). To 
ascertain this hypothesis, the complex of S protein with rfhSP-D was docked to ACE2. S 
protein and rfhSP-D bound to ACE2 via common interacting residues. 
The top ranked docked structure of ACE2 and rfhSP-D had binding energy of -24.30 
kcal/mol. In this pose, rfhSP-D interacted with the virus-binding hotspot residues Ser19, 
Lys31, His34 and Glu35 of ACE2, implying that rfhSP-D could bind to ACE2 in a manner 
that can inhibit ACE2-S protein interaction (Table 2, Figure 1). To corroborate this 
postulation, the complex of ACE2 with rfhSP-D was docked to Spike S. Top ranked pose of 
ACE2-rfhSP-D complex docked with open S protein had binding energy of -33.01 kcal/mol 
and several common interactions between rfhSP-D and ACE2 with S protein 
(Supplementary Figure S1). The docking experiments led us to infer that rfhSP-D could 
bind to both ACE2 and Spike S and prevent ACE2-S protein interaction.
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Single residue in silico mutants of rfhSP-D displayed lower binding affinities to S 
protein and ACE-2
In silico mutational analysis was performed to evaluate the functional importance of residues 
of rfhSP-D that were identified to be involved in the inter-molecular interactions with ACE-2 
and S protein through docking studies (Table 2, Figure 1). rfhSP-D residues Ser328, Gly309, 
Pro307, Thr305, Gln258 of the ACE-2-rfhSP-D complex and Lys229, Glu242, Gly241, 
His220, Gln219 of S protein-rfhSP-D complex were individually substituted to standard 
amino acids. All the mutants demonstrated lower binding affinities except for substitutions 
with similar physicochemical properties (Figure 2), corroborating the importance of the 
mutated residues in intermolecular interactions.
rfhSP-D binds to the immobilised S protein of the SARS-CoV-2 as well as hACE-2
The possible binding between rfhSP-D and S protein hinted by the docking analysis was 
confirmed in vitro via an indirect ELISA. rfhSP-D was found to bind the immobilised S 
protein in a dose-dependent manner (Figure 3a). However, a significant difference in the 
absorbance was observed based on the specificity of the primary antibody used. S protein-
rfhSP-D binding that was probed with the polyclonal antibody against SP-D reported a 
significantly higher absorbance when compared to the wells that were probed with a 
monoclonal antibody directed against the CRD of SP-D. This difference suggests 
involvement of CRD of rfhSP-D with the spike protein and therefore, the CRD was not 
available for interaction with the monoclonal antibody. S protein was also found to bind to 
the FL SP-D. The treatment of rfhSP-D with 10mM EDTA did not significantly alter the 
binding of rfhSP-D and FL SP-D to S protein (Figure 3b). Hence, rfhSP-D and FL SP-D 
bind to the S protein in a dose-dependent but a calcium-independent manner. A similar 
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parallel experiment revealed that rfhSP-D bound ACE2 in a dose-dependent manner (Figure 
3c). 
rfhSP-D inhibits the interaction of S protein and its RBD with biotinylated hACE-2 in a 
calcium-independent manner
Since rfhSP-D was found to bind to the S protein and ACE-2, and as both rfhSP-D and ACE-
2 were predicted to share the same binding site on S protein, rfhSP-D mediated inhibition of 
the interaction between the RBD of S protein of SARS-CoV-2 and ACE-2 was assessed using 
a colorimetric ELISA. 
The wells were coated with either the S protein or its RBD domain that was preincubated 
with rfhSP-D followed by biotinylated hACE-2. The functionality and the range of the assay 
were initially assessed by verifying if the assay could detect the binding of hACE-2 at a 
concentration of 0.12 µg/ml and 0.06 µg/ml. The binding occurred in a dose-dependent 
manner, confirming that the assay can detect binding between S protein or its RBD domain 
with hACE-2 at a concentration as low as 60 ng/ml (Supplementary Figure S2). A decrease 
in binding between S protein and hACE-2 was observed as the concentration of rfhSP-D 
increased (Figure 4; Figure 5). Approximately 50% decrease in S protein-hACE-2 binding 
was observed as rfhSP-D concentration increased 5-fold (Figure 4a).  A similar result was 
observed between the binding of the RBD of S protein and hACE-2. An 8-fold increase in the 
concentration of rfhSP-D was found to decrease RBD-hACE-2 interaction by ~25% (Figure 
5a). No significant difference was observed between the samples with 10mM EDTA and 
without EDTA in terms of rfhSP-D mediated S protein/RBD-hACE-2 binding (Figure 4b; 
Figure 5b).  Hence, rfhSP-D mediated inhibition of the interaction between the RBD of S 
protein or the S protein itself with biotinylated hACE-2 occurred in a calcium-independent 
manner.
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rfhSP-D treatment inhibits SARS-CoV-2 infection and replication
As rfhSP-D is known to induce apoptosis in cancer and immortalised cells (22, 24-26), the 
effect of rfhSP-D on Vero cells was assessed using MTT assay. rfhSP-D treatment had no 
significant effect on the viability of Vero cells (Supplementary figure S3).  At the outset, 
the TCID50 values of the clinical samples were obtained by evaluating the cytopathic effects 
using MTT assay. As expected, when Vero cells were challenged with 100 TCID50, or 50 
TCID50 of viral samples from SARS-CoV-2 clinical samples, a 50% or 25% reduction in cell 
viability was observed, respectively, compared to the viability of uninfected Vero cells, 
confirming the assayed TCID50 values (Figure 6). The control samples showed no significant 
difference in the cell viability than the uninfected Vero cells when the control sample 
volumes equivalent to 100 TCID50 and 50 TCID50 of the matched clinical cases were used. 
The effect of rfhSP-D on the replication of SARS-CoV-2 (100 TCID50/well; MOI 0.01) in 
Vero cells was evaluated by measuring the levels of the RdRp gene of SARS-CoV-2 by RT-
PCR 24h post-infection. Pre-treatment of the positive samples (n=15), comprising of SARS-
CoV-2 with rfhSP-D, led to a reduction in RdRp levels in a dose-dependent manner (Figure 
7; Table S1). The pre-treatment of samples from all categories of SARS-CoV-2 positive 
cases [as representatives, the Figure 7 shows the data for 1S (Cat 2) and 3S (Cat 6)] with 
0.835 µM rfhSP-D led to ~4.5-fold reduction (-4.5 log2) of RdRp transcript compared to the 
untreated positive sample challenged Vero cells. There was no significant difference in the Ct 
values of RdRp gene from the untreated and control sample treated Vero cells. Similarly, pre-
treatment with 1.67 µM rfhSP-D resulted in ~5.5-fold reduction (-5.5 log2) of RdRp mRNA 
expression. Remdesivir, one of the anti-viral drugs proposed for COVID-19, which functions 
by inhibiting viral RNA synthesis, was found to inhibit SARS-CoV-2 replication by ~4-fold 
(-4 log2). Hence, rfhSP-D blocked SARS-CoV-2 infection, in addition to inhibiting the 
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replication of SARS-CoV-2 significantly better than Remdesivir at both tested concentrations 
(0.835 µM and 1.67 µM rfhSP-D). 
As rfhSP-D was found to interact with S protein and ACE-2, proteins that play an integral 
role in viral host cell recognition and entry, the role of rfhSP-D in viral infectivity was 
assessed in a similar manner to replication. Vero cells infected with SARS-CoV-2 positive 
samples (500TCID50/well, MOI 0.05) showed a rfhSP-D dose-dependent decrease in the 
expression levels of the RdRp gene, 2h post-infection (Figure 8; Table S2). Clinical samples 
from all the categories of SARS-CoV-2 patients [As representatives, figure 8 shows the data 
from 2S (Cat 6) and 9AS (Cat 5a)] showed ~ 1.25-fold reduction (-1.25 log2) or ~ 2-fold 
reduction (-2 log2) in RdRp gene expression with the samples pre-treated with either 0.835 
µM or 1.67 µM respectively of rfhSP-D. Remdesivir was used as a control (Remdesivir does 
not inhibit SARS-CoV-2 infection). Thus, pre-treatment of SARS-CoV-2 in the clinical 
sample with rfhSP-D appears to make S protein unavailable to interact with the ACE-2 
receptor on the host cell, thus, reducing the infectivity of the virus and subsequent viral 
replication in a dose-dependent manner.
Discussion
The present study explored the likely protective effect of a recombinant fragment of human 
lung surfactant protein D, rfhSP-D, against SARS-CoV-2. As predicted by the docking study, 
rfhSP-D interacted with the spike protein of SARS-CoV-2, its receptor binding domain 
(RBD) as well as ACE-2. Importantly, these interactions may have contributed to significant 
inhibition of infectivity and replication of SARS-CoV-2 virus present in the clinical samples 
derived from asymptomatic, symptomatic and severe patients of COVID-19 (Figure 9).    
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One of the first steps of the SARS-CoV-2  infection is the binding of the S protein to the host 
cell via, ACE-2 receptor (27). S1 protein is known to interact with ACE-2 receptor via the 
receptor-binding motif (RBM:455-508) in the receptor-binding domain (RBD: aa 319-527) 
with virus binding hotspot residues comprising of Lys31, Glu35 and Lys353 of dimeric 
ACE2 (28-30). Since SP-D interaction with spike protein of SARS-CoV has been reported, 
which shares ~74% homology with the RBD of SARS-CoV-2 (12) and rfhSP-D is known to 
bind to viral surface proteins such as haemagglutinin and neuraminidase of influenza A virus,  
gp120 of human immunodeficiency virus 1 (7, 31), and S protein of SARS-CoV (12), the 
possibility of rfhSP-D binding to the S protein of SARS-CoV-2 was examined. 
In-silico interaction of rfhSP-D with RBD of Spike protein of SARS-CoV-2 revealed that 
Tyr449, Gln493 and Gln498 of RBD overlapped with the residues that are essential for the 
binding of S protein to the target protein ACE-2. The binding of S protein to rfhSP-D or FL 
SP-D was confirmed using an indirect ELISA. A comparatively lower absorbance with the 
monoclonal antibodies raised against the CRD region of human SP-D than the polyclonal 
antibodies could be attributed to the fact that the binding between rfhSP-D and S protein 
occurred through the CRD region of rfhSP-D and FL SP-D. Further, calcium independence 
suggested an involvement of protein-protein interaction. A significant inhibition of the S 
protein-ACE-2 interaction in presence of rfhSP-D suggested that rfhSP-D could interfere 
with the binding of the SARS-CoV-2 to the host cell, an essential step for the infection to 
occur. 
Clinical samples of SARS-CoV-2 were used to assess if rfhSP-D modulated the infectivity 
and replication of the virus (isolation of the virus in the laboratory conditions may introduce 
alterations) in vitro. For assessing replication, qRT-PCR of the RdRp gene, which is essential 
for the replication of viral RNA was measured. Remdesivir was used as a positive control for 
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replication inhibition. Remdesivir, an adenosine analogue, functions by incorporating itself 
into nascent viral RNA chains which results in premature termination, thereby effectively 
inhibiting viral RNA synthesis (32). Downregulated RdRp expression in the Remdesivir 
treated samples clearly validated the platform for evaluating viral replication using clinical 
samples. A dose-dependent reduction of the RdRp mRNA expression in Vero cells, 
challenged with rfhSP-D-pre-treated SARS-CoV-2 positive clinical samples at a higher fold 
change than Remdesivir, suggested a highly potent anti-SARS-CoV-2 activity mediated by 
rfhSP-D. 
Replication kinetic studies involving Vero cells infected with SARS-CoV-2 have 
demonstrated a significant synthesis of viral RNA at ≥ 6 h post-infection (33). As such, any 
viral RNA detected 1-2 h post-infection could be considered to have come from the infecting 
viral particles and not from subsequent viral RNA synthesis or viral replication. Hence, to 
confirm if rfhSP-D played a role in inhibiting SARS-CoV-2 infection, Vero cells were 
infected with SARS-CoV-2 clinical samples at a high concentration (500TCID50; MOI 0.05) 
for 2h. In accordance with the previous reports, no significant effect of Remdesivir on the Ct 
values of Vero cells challenged with clinical samples validated the assay format (34). 
Reduced RdRp transcripts in presence of rfhSP-D demonstrated the ability of rfhSP-D to act 
as an entry inhibitor against SARS-CoV-2. These results suggest that rfhSP-D is a potential 
candidate to be used as an S protein-based inhibitor against SARS-CoV-2 infections. With 
established safety in vivo and therapeutic efficacy against several respiratory pathogens, 
rfhSP-D will effectively combat the nosocomial co-infections in COVID-19 patients. 
There is dysregulated pro-inflammatory cytokine response without protective IFNs in 
response to SARS-CoV-2 mediated lung tissue damage leading to Acute Respiratory Distress 
Syndrome (ARDS). The levels of SP-D were significantly altered in bronchoalveolar lavage 
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of patients of ARDS and were strong predictors of poor prognosis (35, 36). Persistent 
complement activation leads to microangiopathy leading to hypoxia in vital organs. The 
current therapeutic strategy comprises of an antiviral like Remdesivir and 
immunosuppressants such as corticosteroids. Importantly, there is a need to rapidly clear cell 
debris or Damage Associated Molecular Patterns (DAMPs) and polarise protective immune 
response towards a protective one and regulate the complement activation. The rfhSP-D is 
capable of dampening the ‘Cytokine storm’ by rapid clearance of the virus infected cells and 
strengthening the lung capacity by restoring homeostasis (37). 
rfhSP-D has been previously shown to inhibit HIV-1 entry as well successfully thwart the 
cytokine storm in an ex vivo model of human vaginal tissue (38). SP-D has a compelling role 
in correcting lung pathophysiology and injury (39). It is possible that SP-D functions as an 
opsonin after binding to the S protein and helps in viral clearance. As a complement- and 
antibody-independent neutralisation agent against SARS-CoV-2, rfhSP-D may be a viable 
alternative as an inhalation formulation to control COVID-19 infection in 
immunocompromised/deficient people and other populations where vaccination against the 
virus would not be a viable option. These promising results warrant further studies in 
COVID-19 animal models, such as mice humanised with human ACE2 and Syrian hamsters 
(Mesocricetus auratus), to better understand the impact of rfhSP-D in the microenvironment 
of the respiratory system (40).
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Figure Legends
Figure 1: Tripartite interaction between S protein (Green), rfhSP-D (Red) and ACE-2 
(Blue) [A, B (zoomed view)].
ACE-2 residues, Ser19, Lys31, Glu35 and His34, interact with both S protein and rfhSP-D. 
The interactions between S protein and ACE-2 are deduced from the crystal structure (PDB 
ID: 6VW1) and between rfhSP-D, and ACE-2 protein are based on docked complexes. 
Individual intermolecular interactions between (C) S protein (Green) and ACE-2 (Blue); (D) 
S protein (Green) and rfhSP-D (Red) and (E) rfhSP-D (Red) and ACE-2 (Blue). The S 
protein residues, Tyr449, Gln493 and Gln498, participate in intermolecular interactions with 
both ACE-2 and rfhSP-D.
Figure 2: Heatmap representation of effect of single residue mutations of rfhSP-D (y-
axis) on binding energy of docked rfhSP-D complex with (A) ACE-2 and (B) S protein 
using mCSM-PPI2 web server. Each of the rfhSP-D residues involved in interaction with 
virus-binding hotspot of ACE-2 and RBM of S protein were mutated to the standard amino 
acids and its effect on binding energy of the complex was assessed. Most of the mutations led 
to decrease in binding affinity (red cells). Few of the conserved substitutions led to increase 
in binding affinity (blue cells), confirming the functional importance of the mutated residues.
Figure 3: rfhSP-D binds to the immobilised Spike protein (S protein) of the SARS-CoV-
2; immobilised rfhSP-D binds to hACE-2 in a dose-dependent but calcium-independent 
manner
ELISA showing binding of rfhSP-D to the immobilised S protein in a dose-dependent 
manner. Microtiter wells were coated with 0.3 µg/ml (0.54nM) of S protein. rfhSP-D (20, 10 
and 5 µg/ml or 0.334, 0.167, 0.083 µM in PBS with 5mM CaCl2) were added to the wells. 
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Full-length Surfactant Protein D (FL SP-D) (20 µg/ml or 0.038 µM) was also used in a 
similar manner. BSA (20 µg/ml) was used as non-specific protein Control (mean of the 
normalised triplicates ± SEM = 0.07 ±0.006 with polyclonal Ab and 0.025 ±0.006 with 
monoclonal Ab). S protein-SP-D binding was detected with either polyclonal or monoclonal 
(A) antibodies against SP-D. To assess the effect of calcium in the SP-D-S protein 
interaction, rfhSP-D (20, 10 and 5 µg/ml or 0.334, 0.167, 0.083 µM) and FL SP-D (20 µg/ml 
or 0.038 µM) either with/without 10mM EDTA was used in a similar manner and probed 
with polyclonal antibodies against SP-D (B). The binding of immobilised rfhSP-D to hACE-2 
(C) was assessed by coating microtiter wells with 0.1 µg/ml of FL SP-D (1.9 nM) or rfhSP-D 
(16.7 nM). BSA (0.1 µg/ml) was used as non-specific protein Control (mean of the 
normalised triplicates ± SEM = 0.006 ±0.005). Decreasing concentration of hACE-2 (0.12, 
0.06 and 0.00 µg/ml or 0.52, 0.26, 0.0 nM) was added to the wells. The SP-D-hACE-2 
binding was detected with Streptavidin-HRP. The background was subtracted from all data 
points. The data were expressed as the mean of triplicates ± SD. Significance was determined 
using the two-way ANOVA (n = 3) test (ns no significance, **p < 0.05 and ***p < 0.0001) 
Figure 4: rfhSP-D inhibits the interaction between Spike of SARS-CoV-2 and 
biotinylated hACE-2 in a calcium-independent manner
Microtiter wells were coated with 0.3 µg/ml (0.54 nM) of S protein. After blocking, rfhSP-D 
(5, 1 and 0 µg/ml or 83.5 nM, 16.7nM, 0.0 nM) (A) was added and incubated for 1h followed 
by probing with biotinylated human Angiotensin-converting enzyme 2 (hACE-2). To assess 
the effect of calcium in the SP-D-mediated inhibition of S protein-hACE-2 interaction (B), 5 
µg/ml or 83.5 nM of rfhSP-D and FL SP-D (5 µg/ml or 9.5 nM) with/without 10 mM EDTA. 
BSA (5 µg/ml) was used as non-specific protein Control (mean of the normalised triplicates ± 
SEM = 0.297 ±0.005). S protein-hACE-2 binding was detected with Streptavidin-HRP. 
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Background was subtracted from all data points. The data were normalised with 100% S 
protein: hACE-2 binding being defined as the mean of the absorbance recorded from the 
control sample (0 µg/ml of rfhSP-D). The data were presented as the mean of the normalised 
triplicates ± SEM. Significance was determined using the one-way ANOVA (n = 3); (ns no 
significance, and ***p < 0.0001). 
Figure 5: rfhSP-D inhibits the interaction between RBD of Spike protein of SARS-CoV-
2 and biotinylated hACE-2 in a calcium-independent manner
Microtiter wells were coated with 0.1 µg/ml (2.5nM) of S protein RBD. After blocking, 
decreasing concentration of rfhSP-D (1, 0.5, 0.25, 0.125, and 0 µg/ml or 16.7, 8.35, 4.18, 
2.09 nM in PBS with 5mM CaCl2) (A) were incubated for 1h followed by probing with 
biotinylated human Angiotensin-converting enzyme 2 (hACE-2). To assess the effect of 
calcium in the rfhSP-D-mediated inhibition of S protein RBD: hACE-2 interaction (B), 5 
µg/ml (83.5 nM) of rfhSP-D or FL SP-D (5 µg/ml or 9.5 nM) with/without 10mM EDTA was 
used.  BSA (5 µg/ml) was used as non-specific protein Control (mean of the normalised 
triplicates ± SEM = 0.894 ±0.006). S protein RBD-hACE-2 binding was detected with 
Streptavidin-HRP. Background was subtracted from all data points. The data obtained were 
normalised with 100% S protein RBD-hACE-2 binding being defined as the mean of the 
absorbance recorded from the control sample (0 µg/ml of rfhSP-D). The data were presented 
as the mean of the normalised triplicates ± SEM. Significance was determined using the one-
way ANOVA (n = 3); (ns no significance, and ***p < 0.0001).
Figure 6: Determination of TCID50 value of the clinical samples in Vero cells using MTT 
assay
Vero cells (5 x 104/well) were seeded in complete MEM in 96-well culture plates and grown 
overnight at 37°C with 5% CO2. Swab samples of 15 confirmed cases of COVID-19 
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(symptomatic contacts of lab-confirmed cases (Cat 2) (n=2), hospitalised severe acute 
respiratory infections (SARI) patients (Cat 4) (n=3), asymptomatic direct and high-risk 
contacts of lab-confirmed cases (Cat 5a) (n=7) and hospitalised symptomatic influenza-like 
illness (ILI) patients (Cat 6) (n=3) that had tested positive by RT-PCR test for SARS-CoV-2) 
and 15 controls (at different dilutions/well) were added to the cells and incubated for 1h. The 
supernatants were removed, and the wells were washed twice with sterile PBS. Fresh 
complete MEM was added to the wells, and the cells were incubated for 96 h. Viability of the 
cells was evaluated using MTT assay. MTT (0.5 mg/ml) containing medium was added to the 
wells for 4h. The supernatants were removed, and cells were lysed using DMSO. Absorbance 
was measured at 590nm. The data obtained were normalised with 100% cell viability being 
defined as the mean of the absorbance recorded from the control sample (0 TCID50/well) and 
TCID50 units were evaluated in each sample. The same assay was used to validate the 
cytopathic effects of 100TCID50 and 50TCID50 units of the samples. Data for cytopathic 
effects of 100TCID50 units for all 15 cases and 15 controls, has been provided in the 
Supplementary Table S1. The representative data for cases (n=2) and controls (n=2) are 
presented as the mean of the normalised triplicates ± SEM Significance was determined using 
the two-way ANOVA (n = 3) test (ns no significance, **p < 0.01, and ***p < 0.0001). 
Figure 7: rfhSP-D pre-treatment of SARS-CoV-2 significantly inhibited its replication
Vero cells (5 x 104/well) were seeded in complete MEM in 96-well culture plates and grown 
overnight at 37°C under 5% CO2. Cells were washed with sterile PBS twice. SARS-CoV-2 
clinical samples (100TCID50/ well; MOI 0.01) (symptomatic contacts of lab-confirmed cases 
(Cat 2) (n=2), hospitalised severe acute respiratory infections (SARI) patients (Cat 4) (n=3), 
asymptomatic direct and high-risk contacts of lab-confirmed cases (Cat 5a) (n=7) and 
hospitalised symptomatic influenza-like illness (ILI) patients (Cat 6) (n=3) that had tested 
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positive by RT-PCR test for SARS-CoV-2) were preincubated with rfhSP-D [0 µg/ml (0 
µM), 50 µg/ml (0.835 µM) or 100 µg/ml (1.67 µM)] in MEM containing 5mM CaCl2 for 1h 
at RT. The pre-treated or untreated virus in the sample was added to the cells and incubated 
for 1h at 37°C under 5% CO2. The wells were washed with PBS twice, and infection medium 
(MEM+0.3% BSA) was added to the cells and incubated for 24h at 37oC. The supernatants 
were collected, RNA was extracted by Perkin Elmer automated extractor, and subjected to 
qRT-PCR for SARS-CoV-2. For control samples, the volume of the sample taken was 
equivalent to the volume of the case sample (100 TCID50) where no RdRp expression was 
detected. The relative expression of RdRp was calculated using rfhSP-D untreated cells (0 
µM rfhSP-D), infected with respective samples as the calibrator.  Data is provided in 
Supplementary Table S1 and data of representative cases (n=2) is presented as the mean of 
triplicates (n=3).  Error bars represent ± SEM. Significance (compared to 100µM 
Remdesivir) was determined using the two-way ANOVA test (*p ≤ 0.05, and ***p < 0.0001). 
Figure 8: rfhSP-D pre-treatment of SARS-CoV-2 significantly inhibited its infectivity
Vero cells (5 x 105/well) were seeded in complete MEM in 12-well culture plates and grown 
overnight at 37°C under 5% CO2. Cells were washed with sterile PBS twice. SARS-CoV-2 
clinical samples (500TCID50/well, MOI 0.05) (symptomatic contacts of lab-confirmed cases 
(Cat 2) (n=2), hospitalised severe acute respiratory infections (SARI) patients (Cat 4) (n=3), 
asymptomatic direct and high-risk contacts of lab-confirmed cases (Cat 5a) (n=7) and 
hospitalised symptomatic influenza-like illness (ILI) patients (Cat 6) (n=3) that had tested 
positive by RT-PCR test for SARS-CoV-2) were preincubated with rfhSP-D [0 µg/ml (0 
µM), 50 µg/ml (0.835 µM) or 100 µg/ml (1.67 µM)] in MEM containing 5mM CaCl2 for 1h 
at RT and 1h at 4oC. This pre-treated or untreated virus containing sample was added to the 
cells and incubated for 1h at 37oC under 5% CO2. The wells were washed with PBS twice, 
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and infection medium (MEM+0.3% BSA) was added to the cells and incubated for 2h at 
37oC under 5% CO2. The cells were scraped, and the media containing scraped cells were 
collected. RNA was extracted and subjected to RT-PCR for SARS-CoV-2. For control 
samples, the volume of the sample taken was equivalent to the volume of the case sample 
(500 TCID50); no RdRp expression was detected the relative expression of RdRp was 
calculated by using rfhSP-D untreated cells (0 µM rfhSP-D), infected with respective samples 
as the calibrator.  Data is provided in Supplementary Table S1 and data for representative 
cases (n=2) is presented as the mean of triplicates (n=3).  Error bars represent ± SEM. 
Significance [compared to control sample (Cells + Virus)] was determined using the two-way 
ANOVA test (ns no significance, and ***p < 0.0001).
Figure 9: rfhSP-D binds Spike/RBD and hACE-2 and inhibits SARS-CoV-2 infection 
and replication. Interaction of rfhSP-D with RBD/Spike of SARS-CoV-2 and hACE-2 
inhibited the interaction of RBD/Spike and hACE-2, essential for viral entry into the host 
cells. This dual interaction of rfhSP-D plausibly conferred the significant inhibition of 
infection and replication of SARS-CoV-2 in clinical samples. 
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Table 1: Characteristics of clinical samples utilised in the study 
Sample Age Sex Ct value for SARS-CoV-2 E gene 
Ct value for SARS-CoV-2 
RdRp gene Category
1S 32 M 18.5 15.46 2
2S 41 F 17.48 15.36 6
3S  44 M 13.46 12.01 6
4S 39 F 13.22 12.67 2
5S 36 M 12.08 14.55 6
6S 42 F 12.28 9.4 4
7S 37 M 16.26 15.42 4
8S 28 F 17.15 15.62 4
9AS 32 M 10.45 10.8 5a
10AS 31 F 12.32 12.4 5a
11AS 26 M 15.33 12.52 5a
12AS 35 F 10.59 12.4 5a
13AS 38 M 15.77 12.89 5a
14AS 29 F 18.07 10.72 5a
15AS 33 M 15.64 13.81 5a
1C 33 M Nd Nd Control
2C 39 F Nd Nd Control
3C 45 M Nd Nd Control
4C 39 F Nd Nd Control
5C 34 M Nd Nd Control
6C 44 F Nd Nd Control
7C 35 M Nd Nd Control
8C 30 F Nd Nd Control
9C 30 M Nd Nd Control
10C 32 F Nd Nd Control
11C 29 M Nd Nd Control
12C 33 F Nd Nd Control
13C 40 M Nd Nd Control
14C 32 F Nd Nd Control
15C 30 M Nd Nd Control
*Nd = Not detected
Page 32 of 55
 AJRCMB Articles in Press. Published March 30, 2021 as 10.1165/rcmb.2021-0005OC 
 Copyright © 2021 by the American Thoracic Society 
Table 2: Results of docking of S protein, ACE-2, and rfhSP-D














Tyr83 Gly496, Asn487, Tyr489
Glu329 Arg439
Lys353 Tyr505, Gly502





















3 ACE-2 rfhSP-D -24.30
Gln552 Ala274, Tyr314
*The S protein residues in bold are predicted to be part of the common binding site for ACE2 
and rfhSP-D.
$The ACE2 residues in bold interact with both S protein and rfhSP-D (docked structure). 
@The structural coordinates of Phe486 is missing in the open conformation S protein (PDB 
ID: 6VYB).
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Figure 1
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Figure 2
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Figure 3
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Figure 4
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Figure 5
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Figure 6 
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Figure 7
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Figure 8
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Figure 9
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Supplementary Figures.
Supplementary Figure S1: Docked poses of S protein (Green) and rfhSP-D (Red) complex 
with ACE2 (Blue) (A-C) and ACE2 and rfhSP-D complex with S protein (D).
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Supplementary Figure S2: ELISA showing binding of Biotinylated human Angiotensin-
converting enzyme 2 (hACE-2) to immobilised SARS-CoV-2 Spike protein (S protein) 
and the Ribosome Binding Domain (RBD) of the S protein in a linear range
Microtiter wells were coated with 0.3 µg/ml (0.54nM) of S protein, or 0.1 µg/ml of RBD 
(2.5nM) of S protein. Decreasing concentration of hACE-2 (0.12, 0.06 and 0.00 µg/ml or 0.52, 
0.26, 0.0 nM) were added to the wells. S protein or RBD: hACE-2 binding was detected with 
Streptavidin-HRP. Background was subtracted from all data points. The data were expressed 
as the mean of triplicates ± SD. Significance [compared to control sample (0 µg/ml of 
biotinylated hACE2)] was determined using the two-way ANOVA test (***p < 0.0001).
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Supplementary Figure S3: Vero cell viability assay via MTT following treatment with 
rfhSP-D 
5 x 104 Vero cells/ well were seeded in complete MEM in 96-well culture plates and grown 
overnight at 37°C, 5% CO2. The cells were then treated with rfhSP-D (0, 10, 20, 100 μg/ml or 
0, 0.167, 0.334, 1.67 µM) for 24 h. 0.5 mg/ml MTT containing medium was added to the wells 
for 4h. The supernatants were removed, and cells were lysed using DMSO. Absorbance was 
measured at 590nm. Background was subtracted from all data points. The data obtained were 
normalised with 100% cell viability being defined as the mean of the absorbance recorded from 
the control sample (0 µg/ml of rfhSP-D). The data were presented as the mean of the normalised 
triplicates ± SEM. Significance was determined using the two-way ANOVA test and no 
significant reduction in cell viability was observed (ns no significance).
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Supplementary Materials and Methods
Clinical Samples  
The clinical samples (Table 1), nasopharyngeal (NP) and oropharyngeal (OP) swabs (n=30) 
used in this study, were stored at the BSL-3 facility of the Institute of Liver and Biliary 
Sciences, Delhi. These clinical samples (n=15) were from symptomatic contact of lab-
confirmed cases (Cat 2), hospitalised severe acute respiratory infections (SARI) case-patients 
(Cat 4), asymptomatic direct and high-risk contacts of lab-confirmed case (Cat 5a) and 
hospitalised symptomatic influenza-like illness (ILI) case-patients (Cat 6) that had tested 
positive by RT-PCR test for SARS-CoV-2. The samples obtained were placed in the viral 
transport medium (Hanks Balanced Salt Solution (HBSS) supplemented with 2% heat-
inactivated FBS, 100 µg/ml Gentamicin and 0.5 µg/ml of Amphotericin B. NP and OP samples 
(n=15) that tested negative by RT-PCR test for SARS-CoV-2 were used as controls. The 50% 
Tissue culture Infective Dose (TCID50) of the clinical samples obtained was confirmed using 
an MTT assay. Briefly, 5 x 104 Vero cells in Vero growth media (MEM Glutamax, 
supplemented with 10% Fetal Bovine Serum, 1% v/v Penicillin-Streptomycin and 1%v/v 
sodium pyruvate [Gibco, Thermofisher]) were seeded in a 96 well plate and grown overnight. 
The clinical samples from the 15 confirmed COVID-19 patients, and the 15 controls were 
added to the cells and incubated for 1h. Post incubation, the wells were washed with PBS twice, 
and fresh Vero growth medium was added to the cells. The cells were then incubated for 96 h 
at 37oC, 5% CO2. A 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
assay was performed to assess the viability of the cells by incubating the cells with 12mM of 
MTT for 4 h at 37oC, 5% CO2. The formazan created was dissolved using DMSO, and the 
samples were read at 590 nm using a microplate reader.
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In silico Analysis
The co-crystallised structure of human ACE-2 receptor with Spike S protein (PDB id: 6VW1) 
was separated into its receptor (ACE-2) and ligand (Spike S) components. The receptor and 
ligand were then re-docked using Patchdock web server (E1, E2) to validate the docking 
protocol. The therapeutic agent, rfhSP-D trimer, (PDB id: 1PW9) was individually blind 
docked with the structure of RBD of S protein in the open conformation (PDB id: 6VYB) and 
dimeric ACE-2 (PDB id: 6VW1) using Patchdock. Top 100 docked poses were selected and 
further refined using FireDock web server (E3, E4) for calculation of global free energy. The 
top 5 refined structures were filtered based on interactions between receptor binding motif 
(RBM) of S protein, CRD (CRD:  aa 240-355) of rfhSP-D and N-terminal of ACE2. The effect 
of binding of trimeric rfhSP-D to S-protein and dimeric ACE2 on ACE2–S protein interaction 
was evaluated by further docking the docked complex of S protein and rhfSP-D with ACE2 
and ACE2 and rfhSP-D with S protein using Patchdock.
Expression and Purification of a Recombinant Fragment of Human SP-D Containing 
Neck and CRD Regions
The expression and purification of rfhSP-D from E. coli was performed as previously described 
(E5, E6). Briefly, the pUK-D1 plasmid that codes for the 8 Gly-X-Y repeats, neck and CRD 
regions of human SP-D was transformed into Escherichia coli BL21 (λDE3) pLysS 
(Invitrogen). The transformed colonies (selected by ampicillin resistance) were grown in Luria-
Bertani media supplemented with a final concentration of 100 µg/ml ampicillin and 34 µg/ml 
chloramphenicol (Sigma-Aldrich) to an OD600 of 0.6. The bacterial culture was then induced 
to produce the recombinant protein by the addition of 0.5 M isopropyl β-d-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) and was allowed to grow for a further 3 h. Post 
incubation, the bacteria were harvested and lysed using lysis buffer (50 mM Tris–HCl pH7.5, 
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200 mM NaCl, 5 mM EDTA pH 8, 0.1% v/v Triton X-100, 0.1 mM phenyl-methyl-sulfonyl 
fluoride, 50 µg/ml lysozyme) and sonicated (five cycles, 30 s each). The sonicate was harvested 
via centrifugation at 12,000 × g for 30 min. This was followed by solubilisation of inclusion 
bodies in refolding buffer (50 mM Tris–HCl pH 7.5, 100 mM NaCl, 10 mM 2-
Mercaptoethanol) containing 8 M urea. and stepwise dialysis of the solubilised fraction against 
refolding buffer containing 4 M, 2 M, 1 M, and no urea. rfhSP-D was purified from the 
dialysate by affinity chromatography using a maltose agarose column (5 ml; Sigma-Aldrich). 
The bound rfhSP-D to the maltose was eluted using elution buffer (50 mM Tris–HCl, pH 7.5, 
100 mM NaCl, and 10 mM EDTA) and passed through a PierceTM High-Capacity Endotoxin 
Removal Resin (Thermofisher) to remove endotoxin. Finally, the endotoxin levels were 
measured via the QCL-1000 Limulus amoebocyte lysate system (Lonza) and found to be <5 
pg/µg of rfhSP-D. The purified rfhSP-D was subjected to western blotting after running on 
12% w/v acrylamide SDS-PAGE to assess purity and immunoreactivity (E5).
ELISA
Assays to determine the binding of the S protein or its RBD of SARS-CoV-2 was performed 
using the SARS-CoV-2 (COVID-19) Inhibitor Screening Kit from Acrobiosystems (EP-105) 
as per the manufacture’s protocol. Briefly, S protein or RBD protein diluted in Coating Buffer 
(15 mmol/L sodium carbonate (Na2CO3), 35 mmol/L sodium hydrogen carbonate (NaHCO3), 
pH 9.6) to a final concentration of 0.3 µg/ml or 0.1 µg/ml respectively were added to 96 well 
plates and incubated overnight (~16 h) at 4oC. The uncoated protein was removed by washing 
the wells with Wash Buffer (PBS with 0.05% (v/v) Tween-20, pH 7.4) three times. The wells 
were then blocked using the Blocking Buffer (PBS with 0.05% (v/v) Tween-20 and 2% (w/v) 
bovine serum albumin (BSA), pH 7.4) for 1.5 h at 37oC. 
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To assess the direct binding of rfhSP-D to S protein, rfhSP-D (20, 10 and 5 µg/ml) were added 
to the wells. The plate was then incubated for 1 h at 37oC, and any unbound protein was 
removed by washing the wells three times with the wash buffer. The wells were probed using 
either polyclonal or monoclonal antibodies against SPD at a dilution of 1:5000 for 1 h at 37ºC 
to detect S protein-rfhSP-D binding. Unbound antibodies were removed by washing three times 
using the wash buffer. Anti-mouse IgG-Horseradish peroxidase (HRP) (Cat # 31430, 
Invitrogen), anti-rabbit IgG HRP (Cat # 31466, Invitrogen) or Protein A HRP (Cat # 18-160, 
Merck) at 1: 5000 dilution was used secondary antibodies by adding them to the respective 
wells of the appropriate primary antibodies and incubating them for 1 h at 37ºC. Following 
washes with wash buffer three times, the binding was detected using 3,3′,5,5′-
Tetramethylbenzidine (TMB) substrate (100 µl/well) (DuoSet ELISA Ancillary Reagent Kit, 
R&D Systems) as per the manufacturer’s instruction, followed by stopping the reaction using 
1M sulphuric acid (100 µl/well) (Cat # Q29307, Thermofisher). The plate was read at 450 nm 
using a microplate absorbance reader (Synergy H1 multimode plate reader, Biotek). Full-length 
Surfactant Protein D (FL SP-D) (20 µg/ml) was also used in a similar manner to assess the 
binding of S protein to FL SP-D. A similar experiment was carried out in parallel using rfhSP-D 
(20, 10 and 5 µg/ml), or FL SP-D (20 µg/ml) supplemented with 10mM EDTA and probed 
with polyclonal antibodies against SPD (1:5000) to evaluate if the S protein-SP-D binding was 
calcium-dependent.
The binding of rfhSP-D or FL SP-D to ACE-2 was evaluated using a similar experiment as 
above. Briefly, FL SP-D (0.1 µg/ml) or rfhSP-D (0.1 µg/ml) were coated in a 96 well plate and 
probed with decreasing concentration of ACE-2 hACE-2 (0.12, 0.06 and 0.00 µg/ml). The 
binding was detected using streptavidin tagged with HRP (1:5000) (EP-105, Acrobiosystems), 
and the colour was developed as described above.
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In a separate experiment to assess if rfhSP-D inhibited the interaction between the S protein 
and biotinylated human Angiotensin-converting enzyme 2 (hACE-2), decreasing concentration 
of rfhSP-D (5, 1 and 0 µg/ml) were added to wells coated with S protein (0.3 µg/ml) and 
blocked as described above. The plate was incubated for 1h at 37oC and washed with the wash 
buffer three times to remove any unbound proteins. Biotinylated hACE-2 was added to the 
wells and plate was incubated for 1h at 37oC. After washing, the S protein-hACE-2 binding 
was measured by probing the wells with the HRP tagged Streptavidin antibody (1:5000) for 1h 
at 37oC. Colour was developed using 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate. The 
reaction was stopped using 1 M H2SO4, and the absorbance was read at 450 nm using a 
microplate absorbance reader. rfhSP-D (5 µg/ml) supplemented with either with 10mM EDTA 
was used in a similar manner to evaluate if the rfhSP-D mediated inhibition of the interaction 
between the S protein and biotinylated hACE-2 occurred in a calcium-independent manner. 
rfhSP-D mediated inhibition of the interaction between the RBD of SARS-CoV-2 S protein 
and biotinylated hACE-2 was also assessed in a similar manner.
Vero Cell Infection Assay 
Vero cell line (derived from African green monkey epithelial Kidney cells) (ATCC® CCL–
81™) (5x104) were cultured for 16 h in each well of a 12 well plate in serum-free medium 
(MEM Glutamax, containing 1% v/v Penicillin-Streptomycin and 1%v/v sodium pyruvate 
[Gibco, Thermofisher]). SARS-CoV-2 clinical samples (100 TCID50/ well, MOI 0.01) were 
preincubated with rfhSP-D [0 µg/ml (0 µM), 50 µg/ml (~2.5µM) or 100 µg/ml (~5µM)] in 
MEM containing 5mM CaCl2 for 1h at RT and 1h at 4oC. This pre-treated or untreated virus 
was added to the cells (Cells + rfhSP-D + Virus).  After 1h incubation at 37ºC, 5% CO2, the 
medium was removed, and cells were washed with PBS to remove any unbound CoVs. 
Infection medium (MEM+0.3% BSA) was added to the cells and incubated for 24 h to assess 
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replication.  The cells were then harvested by scraping with a sterile disposable cell scraper 
and centrifuged at 1500 x g for 5 minutes. Total RNA was extracted using the Perkin Elmer 
automated extractor and subjected to Real-time RT-PCR for SARS-CoV-2 using Pathodetect 
kits from MyLabs, as per manufacture’s protocol. For the replication analysis of SARS-CoV-
2, Ct value for SARS-CoV-2 RNA dependent RNA polymerase (RdRp) gene was used for 
analysis. Cells incubated with rfhSP-D, without virus was used protein control (Cells + rfhSP-
D) and cells incubated with BSA (100µg/ml), and the virus was used as non-specific protein 
control (Cells + Virus). Sterile PBS with the virus was used as negative control.
The effect of rfhSP-D on viral infection was assessed by culturing Vero cells (5x105) in a 12 
well plate in serum-free MEM. SARS-CoV-2 clinical samples (500 TCID50/ well, MOI 0.05) 
were treated with rfhSP-D and added to the cells as described above. However, after the 
addition of the infection medium, the cells were incubated only for 2h, after which they were 
harvested, and Real-time RT-PCR was performed using the same controls and parameters 
described above. 
Statistical Analysis
Statistical analysis and Graphs were generated using GraphPad Prism 8.0 software. Significant 
values were considered as indicated in the figure legends between treated and untreated 
conditions. Error bars show the SD or SEM, as indicated in the figure legends.
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Supplementary Raw Data
Table S1: Mean Ct values of SARS-CoV-2 RdRp gene for the replication assay









Mean Ct value 
± SD of samples 
treated with 50 
µg/ml rfhSP-D
Mean Ct value ± 
SD of samples 
treated with 100 
µg/ml rfhSP-D
Mean Ct value ± 









1S 19.900 ± 
0.327
23.900 ± 0.245 26.100 ± 0.327 24.800 ± 0.163 56.22 ± 5.5 Nd
2S 19.650 ± 
0.531
23.833 ± 1.087 25.700 ± 0.163 25.000 ± 0.163 45.86 ± 4.7 Nd
3S  20.900 ± 
0.163
22.400 ± 0.163 26.600 ± 0.327 25.900 ± 0.163 47.99 ± 3.5 Nd
4S 20.900 ± 
0.163
21.800  ± 0.082 26.200 ± 0.082 26.250 ± 0.367 46.44 ± 6.3 Nd
5S 21.600 ± 
0.082
24.350  ± 0.204 27.000 ± 0.163 - 52.73 ± 3.2 Nd
6S 19.700 ± 
0.082
 26.150 ± 0.367 - 55.4 ± 6 Nd
7S 20.550 ± 
0.204
 25.750 ± 0.122 - 48.4 ± 5.1 Nd
8S 20.800 ± 
0.163
 26.500 ± 0.245 - 47.34 ± 2.1 Nd
9AS 19.350 ± 
0.122
 27.100 ± 0.163 25.700 ± 0.245 58.1 ± 7.5 Nd
10AS 20.600 ± 
0.245
 27.150 ± 0.286 25.950 ± 0.531 49.62 ± 3.9 Nd
11AS 20.450 ± 
0.204
26.050 ± 0.122   64.3 ± 7.5 Nd
12AS 20.500 ± 
0.082
 27.150 ± 0.122   45.8 ± 3.85 Nd
13AS 21.050 ± 
0.122
 26.950 ± 0.204   51.7 ± 4.2 Nd
14AS 19.500 ± 
0.163
 26.200 ± 0.245   57.3 ± 5.7 Nd
15AS 21.250 ± 
0.204
 26.150 ± 0.367   53.8 ± 6.6 Nd
1C Nd Nd Nd Nd 97.34 ± 5.5 Nd
2C Nd Nd Nd Nd 88.4 ± 7.3 Nd
3C Nd Nd Nd Nd 87.9 ± 4.7 Nd
4C Nd Nd Nd Nd 91.2 ± 6.4 Nd
5C Nd Nd Nd Nd 95.33 ± 4.5 Nd
6C Nd Nd Nd Nd 87.34 ± 8.3 Nd
7C Nd Nd Nd Nd 85.7 ± 9.3 Nd
8C Nd Nd Nd Nd 97 ± 6.7 Nd
9C Nd Nd Nd Nd 88.53 ± 7.2 Nd
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10C Nd Nd Nd Nd 89.6 ± 7.7 Nd
11C Nd Nd Nd Nd 93.43 ± 5.6 Nd
12C Nd Nd Nd Nd 95.8 ± 6.2 Nd
13C Nd Nd Nd Nd 89.45 ± 7.3 Nd
14C Nd Nd Nd Nd 85.77 ± 9.2 Nd
15C Nd Nd Nd Nd 93.8 ± 5.8 Nd
*Nd = Not Detected
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Table S2: Mean Ct values of SARS-CoV-2 RdRp gene for the infection assay
500 TCID50 (MOI 0.05)
Sample
Mean Ct value ± 
SD of samples 
treated with 0 
µg/ml rfhSP-D 
Mean Ct value ± 
SD of samples 
treated with 50 
µg/ml rfhSP-D
Mean Ct value ± 
SD of samples 
treated with 100 
µg/ml rfhSP-D
Mean Ct value ± SD of 












































21.850 ± 0.122 Nd
1C Nd Nd Nd Nd Nd
2C Nd Nd Nd Nd Nd
3C Nd Nd Nd Nd Nd
4C Nd Nd Nd Nd Nd
*Nd = Not Detected
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